Sakar Healthcare Limited has informed the Exchange about allotment of 3,00,000 Equity Shares upon conversion of Fully Convertible Warrants
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sakar Healthcare has allotted 3,00,000 equity shares (face value Rs. 10 each) to four non-promoter allottees upon conversion of the remaining fully convertible warrants originally issued on 28 December 2023. The company received Rs. 8.64 crore as the balance 75% warrant exercise price at Rs. 288 per share, with the total issue price originally set at Rs. 384 per share (including Rs. 374 premium). The allottees are Hi-Tech Chemicals Limited (2,00,000 shares), Hemant Gadodia (34,000), Prakash Diwan (33,000), and Sunil Kabra (33,000). With this conversion, all 5,00,000 warrants issued in 2023 have now been fully converted (2,00,000 were converted in December 2024), and no warrants remain outstanding. The paid-up equity capital has increased to Rs. 22.25 crore, comprising 2,22,49,910 equity shares.
This is a routine, fully-disclosed conversion of previously issued warrants, resulting in minor dilution of about 1.35%. The company has received Rs. 8.64 crore of fresh capital, and with no warrants left outstanding, there is no further pending dilution from this 2023 issuance. The newly allotted shares will be subject to SEBI lock-in restrictions, limiting near-term supply overhang.